+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CSF monoamine metabolites of depressed patients during illness and after recovery

CSF monoamine metabolites of depressed patients during illness and after recovery

Acta Psychiatrica Scandinavica 69(4): 333-342

Repeated lumbar punctures in 16 healthy volunteers showed reproducible concentrations of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) in cerebrospinal fluid (CSF). In seven depressed patients, studied during two or three illness periods, the metabolite concentrations were also fairly stable. In 11 patients CSF concentrations of 5-HIAA, but not of HVA, were higher after recovery than during depression. This increase of 5-HIAA after recovery was confined to patients whose initial serotonin metabolite levels were low. The finding constitutes further evidence of a biochemical heterogeneity within the depressive disorders, and suggests that patients whose CSF 5-HIAA is low during a depressive episode may have a less stable serotonin system than other patients with depressive illness.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 042429329

Download citation: RISBibTeXText

PMID: 6202099

Related references

CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. European Psychiatry 23(5): 356-359, 2008

Monoamine metabolites in cerebrospinal fluid of depressed patients during treatment with mianserin or amitriptyline. Journal of Affective Disorders 4(3): 219-226, 1982

Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients. Journal of Affective Disorders 14(2): 99, 1988

CSF monoamine metabolites and lethality of suicide attempts in depressed patients with alcohol dependence. European Neuropsychopharmacology 17(1): 12-15, 2007

Biological markers in depression. Monoamine metabolites in urine of depressed patients and normal subjects. Pharmacopsychiatry 18(6): 347-350, 1985

Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients. Psychiatry Research. 52(3): 259-264, 1994

Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Archives of General Psychiatry 46(7): 609-612, 1989

Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiatry Research 4(1): 21-29, 1981

Plasma sex hormones and urinary biogenic amine metabolites during treatment of male depressed patients with the monoamine oxidase inhibitor moclobemide. Neuroendocrinology Letters 13(1): 49-56, 1991

Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biological Psychiatry 56(6): 418-426, 2004

Monoamine neurotransmitters and their metabolites in depressed suicide victims. British Journal of Pharmacology 90(Suppl.): 286P, 1987

Changes on recovery in the concentrations of tryptophan and the biogenic amine metabolites in the cerebrospinal fluid of patients with affective illness. Psychological Medicine 3(3): 319-325, 1973

Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychological Medicine 23(2): 387-395, 1993

Loss, humiliation and entrapment as appraisals of schizophrenic illness: a prospective study of depressed and non-depressed patients. British Journal of Clinical Psychology 37(3): 259-268, 1998

Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section 5(3): 193-202, 1993